Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Inflammatory, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD18/ITGB2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD18 (ITGB2) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CD18 Products |
| Gene Delivery | CD18 (ITGB2) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (Flow Cytometry & Cell Adhesion assays). |
View CD18 Products |
| Benchmark Ab | Anti-CD18 Recombinant Antibody (Erlizumab sequence) Recombinant positive control for functional blocking. |
View CD18 Products |
| Validator | CD18 (ITGB2) siRNA Set For target knockdown validation in primary leukocytes. |
View CD18 Products |
| Related Target A | CD11a (ITGAL) Heterodimerization partner forming LFA-1; critical for T-cell adhesion. |
View CD11a Products |
| Related Target B | CD11b (ITGAM) Heterodimerization partner forming Mac-1; key mediator of myeloid cell migration. |
View CD11b Products |
| Related Target C | ICAM1 Primary endothelial ligand for CD18/CD11 complexes; vital for adhesion assays. |
View ICAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (Active vs. Inactive states) | HEK293 expressed proteins preserving native disulfide bonds and glycosylation patterns. |
| Heterodimer stability (CD18 must pair with CD11 subunits) | Co-expressed CD11/CD18 heterodimeric proteins optimized for native stoichiometry. |
| Lack of controls | Clinical benchmark antibodies (Erlizumab biosimilar) included |
| Off-target integrin cross-reactivity | High-purity Integrin Beta family panel (Beta-1, Beta-3, Beta-7) for counter-screening |
Live CD18/ITGB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD18 (Integrin beta-2) is undergoing a major renaissance. Historically explored for acute inflammatory conditions like ischemia-reperfusion injury (where early antibodies like Erlizumab faced clinical hurdles due to dosing and patient selection), the focus has shifted. Today, R&D is pivoting toward selective heterodimer modulation (LFA-1 vs. Mac-1) and conformation-specific antibodies that block leukocyte extravasation without triggering systemic leukocyte adhesion deficiency (LAD)-like side effects.
Furthermore, CD18 is emerging as a novel immuno-oncology target. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) utilize CD18/CD11b networks to home into the tumor microenvironment, contributing to immunotherapy resistance. Next-generation therapies aim to disrupt this homing mechanism to restore checkpoint inhibitor sensitivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic institutions, Biotech startups | Autoimmune diseases, Dry Eye Disease, Ischemia | Conformation-specific binding assays (Requires native HEK293-expressed CD11/CD18) |
| Small Molecule Inhibitors | Global Pharma | Psoriasis, Inflammatory Bowel Disease (IBD) | High-throughput screening (Requires stable CD18-expressing Lentivirus cell lines) |
| Antisense / RNAi | RNA Therapeutics specialists | Severe systemic inflammatory syndromes | In vitro knockdown verification (Requires validated CD18 siRNA sets) |